Navigation Links
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
Date:11/19/2009

SEATTLE, Nov. 19 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER) today announced unaudited financial results for the third quarter ended September 30, 2009. For the three months ended September 30, 2009, Omeros reported a net loss of $3.9 million, or $1.34 per share, as compared to a net loss of $7.4 million, or $2.54 per share, for the same period in 2008. For the nine months ended September 30, 2009, the Company reported a net loss of $15.5 million, or $5.29 per share, as compared to a net loss of $17.4 million, or $6.07 per share, for the same period in 2008.

On October 7, 2009, Omeros priced its initial public offering (IPO), which generated net proceeds to the Company of approximately $61.8 million from the sale of 6,820,000 shares of its common stock at a price of $10.00 per share.

"Our IPO afforded Omeros the resources to advance aggressively our pipeline of clinical and preclinical programs. We expect that the proceeds will allow us to complete our ongoing Phase 3 clinical trials for our lead PharmacoSurgery(TM) product, OMS103HP, and fund its commercial launch into the arthroscopy market. We also recently amended a key agreement for our GPCR program, providing us with additional opportunities to realize the value of the program while limiting our expenditures," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "Throughout the course of next year, we look forward to releasing data from our Phase 3 arthroscopic program as well as meeting additional clinical milestones for our ophthalmologic and urologic programs."

Financial Results

Total operating expenses for the three months ended September 30, 2009 were $5.0 million compared to $8.2 million for the same period in 2008. The decrease in operating expenses in the third quarter of 2009 as compared to the same peri
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Commences Initial Public Offering of Common Stock
10. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in medical imaging ... vital sign monitoring in ICU to 3D skull printing analysis for Neurosurgery, ONYX ... clinical decisions with simultaneous access to high precision medical images and electronic health ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... equipment, to creating professional commercial video content, to analysis of athletic performance. Producing ... events that go by too quickly to process with the naked eye. ...
(Date:9/1/2015)... ... September 02, 2015 , ... Spirax Sarco , the leader in products ... Spirax Sarco Anytime. This platform, offering unique online ordering capabilities, is only available ... Log on to Spirax Sarco Anytime and within minutes you can be making ...
(Date:9/1/2015)... 2015 Prostate cancer is the second ... men. One in seven men will be diagnosed ... are diagnosed annually. That said, not every diagnosis ... new technique, MRI Fusion Biopsy, to more accurately ... only the affected areas and monitoring areas ...
Breaking Biology Technology:Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Spirax Sarco Announces New Features to Anytime Platform 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4
... AUSTIN, Texas, Sept. 6, 2011 Genprex, Inc., ... first product candidate, the nanomolecular cancer therapy CNVN202, will be ... establishing the Oncoprex brand in the oncology sector ... when approved, Oncoprex will be used to unlock ...
... The inaugural  European Neurotech ... week. It features keynotes on the state of the European ... project presentations on next generation treatments emerging in the EU ... like Alzheimer , s, addiction, depression, schizophrenia, Parkinson ...
... QIAGEN assay for JAK2 V617F mutation aims to identify patients ... monitor responses to therapy - Lilly will co-develop ... biomarker underpins potential future expansion with additional Pharma compounds targeting ... Prime Standard: QIA) today announced that it has entered into ...
Cached Biology Technology:Genprex Announces New Branding 2High-Level Neurotech Summit Brings Companies, Researchers and Investors Together in Helsinki 2High-Level Neurotech Summit Brings Companies, Researchers and Investors Together in Helsinki 3QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 2QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 3QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers 4
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International ... it has entered into a Definitive Agreement to ... of iris authentication market leader EyeLock through an ... will have a controlling interest in the acquiring ... to completion of due diligence.  Expanding on its ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions , ... entire spectrum of clinical research, is proud to announce ... company,s comprehensive SaaS-based eClinical technology platform, has led the ... first two quarters of 2015.   Q2 2015 and ... quarters measured by contract value sold in the company,s ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s ... in 2015 that relate to sales of FPC1155 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... smartphone manufacturer in China and we are ... for Z1 , its ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... PHILADELPHIA A strong skeleton is less likely to ... glass of milk might be the way to block ... Institute in Concord, Australia. Using a mouse model of ... deficiency may increase the tendency of advanced breast cancer ...
... researcher has developed a new technique that can ... the bacteria which causes the most common bout ... from QUT,s Faculty of Science, has developed a ... to pinpoint the bacteria Campylobacter jejuni. "Campylobacter ...
... software kits applies advanced image, processing technology to the difficult ... ... BEDFORD, Mass., Oct. 1 Aware, Inc. (Nasdaq:,AWRE), a global ... CaptureSuite, a family of software,development kits used to perform rapid ...
Cached Biology News:Dietary calcium could possibly prevent the spread of breast cancer to bone 2Fighting the spread of food poisoning 2Aware, Inc. Introduces Biometrics Software for Tenprint Autocapture 2Aware, Inc. Introduces Biometrics Software for Tenprint Autocapture 3
XA7 B6...
... motor and ballscrew technologies, the ... solutions that include all the ... motors., , XY and ... high-flex cabling for power, signals, ...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
...
Biology Products: